Eli Lilly's experimental next-generation drug retatrutide outperformed a lower-dose version of Novo Nordisk's Ozempic on blood sugar control and showed more than double weight loss in a study of adults with Type 2 diabetes. The head-to-head trial compared 9 mg and 12 mg...
Continue reading...
[ H/T Newsmax ]
